Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: S&P Capital IQ Quantitative Report
Provider: S&P Capital IQ Quantitative Report
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bio-Rad Laboratories Inc Lowers FY 2012 Revenue Guidance-Conference Call

Tuesday, 6 Nov 2012 10:00pm EST 

Bio-Rad Laboratories Inc announced that in the last call it has guided currency neutral revenue growth to be at the low end of 3.5% to 4.5% range for fiscal 2012. Given year to date currency neutral growth of about 2.7% and combined with the continued economic challenges, especially in the European region, it now believe the full year currency neutral sales growth for fiscal 2012 will likely remain in that same 2.5% to 3% range have experienced so far this year. The Company reported revenue of $2.074 billion in fiscal 2011. 

Company Quote

0.21 +0.18%
22 Sep 2014